**COMPANY REGISTRATION NUMBER : 7225131** # **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE UNAUDITED FINANCIAL STATEMENTS FOR YEAR ENDED 30 JUNE 2022** **Charity Number : 1136067** ## Edmund Carr LLP Chartered Accountants 146 New London Road Chelmsford Essex CM2 OAW ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **FINANCIAL STATEMENTS** ## **YEAR ENDED 30 JUNE 2022** **----- Start of picture text -----**
CONTENTS PAGE
Company information 1
Trustees' annual report 2
Independent Examiner's report to the Trustees 11
Statement of financial activities 12
Balance sheet 13
Notes to the financial statements 14
**----- End of picture text -----**
## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **COMPANY INFORMATION** ## **YEAR ENDED 30 JUNE 2022** **Charity Number** 1136067 **Company Number** 7225131 **Registered Office** 38-43 Lincoln's Inn Fields London WC2A 3PE ## **THE TRUSTEES** The Trustees of the charity are also the directors of the charity. The Trustees who served the charity during the year were as follows: Mr Hassan Malik (Resigned 21/11/2021) President (to 21/11/2021) Mr Zaed Hamady President (from 22/11/2021) Vice President (to 21/11/2021) Professor Michael Douek Vice President (from 22/11/2021) Honorary Secretary (to 21/11/2021) Mr John Whiting EJSO Representative (from 22/11/2021) Honorary Treasurer (to 21/11/2021) Mr Michael Shackcloth Honorary Treasurer (from 22/11/2021) EJSO Representative (to 21/11/2021) Mr Anant Desai Honorary Secretary (from 22/11/2021) Professor Jim Khan Meeting Secretary Mr Avi Agrawal (Appointed 21/11/2021) Mr Edmund Leung Professor Derek Manas Mr Aaron Quyn Professor Richard Shaw (Resigned 21/11/2021) Mr Paul Skaife (Appointed 21/11/2021) Professor Jayant Vaidya -1- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE TRUSTEES' ANNUAL REPORT** ## **YEAR ENDED 30 JUNE 2022** The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the year ended 30th June 2022. The Trustees of the charity as shown on page 1 are also the directors of the charity. ## **Objectives and Activities** The Charity’s objectives are: _**To advance the science, practice, and art of surgical oncology**_ for the benefit of patients with cancer; and to _**promote research, training, and education in surgical oncology**_ for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately. The Association seeks to act as an umbrella organisation for those working in all surgical cancer specialties and cancer research. In addition, the Society focuses on innovation in cancer care and support for future workforce training and development. The Trustees pay due regard to the Charity Commission’s guidance on public benefit when deciding what activities the Charity should undertake. ## _**Portfolio of BASO Prizes and Awards**_ The Association takes great pride in its **portfolio of awards** to encourage our junior colleagues and to support their interest in the field of surgical oncology, its research and care of cancer patients. Follow link for more details: https://baso.org.uk/education-training.aspx. The Society continues awarding the following prizes at its annual scientific meeting: - **Alan Edwards Memorial Prize** is awarded to the best poster presentation. - **Ronald Raven Presentation Prize** is awarded to the best oral paper presentation. - **BASO~ACS Presentation Prize** , formerly known as BJS Prize, is awarded to the best oral paper presentation. Due to the change of structure, the British Journal of Surgery Society (BJSS) discontinued to support this prize. In 2019, BASO Council agreed to sponsor this prize to ensure continuity to the BJS Paper Presentation Prize awarded at the BASO Meeting. - **BASO Trainees (poster/oral presentation) Prize** is awarded to the best poster and oral paper presentations at the BASO Trainees Meeting. To expand its commitment to all cancer-related professionals, BASO announced the following new prizes: - **BASO Trainees Audit/QIP Prize** to support and encourage trainees, those involved with audit and quality improvement with a view of improving care to patients, in particular, cancer patients. - **BASO Multidisciplinary Prize** to recognise the work done by our Non-Medical Professional colleagues in supporting cancer patients. This unique award is designed to highlight any research, audit, quality improvement, health service provision/development, cancer patient pathway study, cancer survivorship study. - **BASO Medical Student Prize** to support and encourage medical students with an interest in surgical oncology. Each year, to support and encourage trainees interest in the field of surgical oncology, BASO offers an array of prizes for the best surgical oncology presentation by a trainee at the annual scientific conference of the ASGBI, ASiT, SCTS and of each of the Surgical Specialty Associations. -2- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **TRUSTEES' ANNUAL REPORT (continued)** ## **YEAR ENDED 30 JUNE 2022** Over the years, BASO has developed a prestigious portfolio of Awards presented to surgeons and trainees in recognition of their outstanding achievement and contribution to the cancer surgery; its research and education. In addition to **Ronald Raven Lifetime Achievement Award** , **Geoff Oats Award** and **Uccio Querci della Rovere Award** , this year BASO inaugurated - **BASO Medal for Excellence** to mark the 50th Anniversary of the founding of the Association, the BASO Council inaugurates the British Association of Surgical Oncology Medal for Excellence to recognise the role of individual surgeon or teams in the advancement of cancer care. This award is inaugurated at the 2021 BASO Annual Scientific Conference and will be presented to a professional or a team in recognition of their outstanding achievements in the field of cancer surgery: excellence in research, clinical practice, education and innovation. This international award will be presented on a 5 year basis and will be open to all members and non-members of the Association for their contribution to UK cancer surgery. BASO is honoured have presented the very first award to Professor Freddie Hamdy.Follow link for more details: https://baso.org.uk/baso~acs-conferences/baso-50th- anniversary meeting.aspx ## _**BASO Grants**_ BASO is expanding its portfolio of research grants to support research. Follow link for more details: https://baso.org.uk/education-training.aspx **BASO Raven Travelling Fellowship** - (formerly known as Ronald Raven Travelling Fellowship) was endowed in 1993 by the Ronald Raven Trustees in memory of Ronald W. Raven, the Founder of the Association. BASO Continues to fund and award this fellowship, which has now increased to £3,000, each year to aspiring trainees to support them to expand their skills and experience in the surgical cancer treatment. **BASO (NIHR) Research Project Grant** - BASO continues to be a non-commercial partner with the National Institute of Health Research (NIHR) and delivered a successful annual research project grant scheme to assist surgeons in undertaking research projects related to surgically linked cancer care. This grant was open for discrete projects and a study awarded this grant is automatically eligible for consideration for the Clinical Research Network Support, thereby, is considered for being a portfolio study.In 2021, BASO has announced a new Research Grant in Cancer Surgery, in partnership with the Rosetrees Trust, that will replace the BASO (NIHR) Research Project Grants from 2022 onwards. **BASO/Rosetrees Research Grants in Cancer Surgery -** In celebration of BASO’s 50 years, BASO National Committee announced a new research grants in cancer surgery in partnership with the Rosetrees Trust. The research grants are for up to £50,000 over 3 years and will be match funded by Rosetrees Trust. The first round of the grants were awarded at BASO’s 50[th] Anniversary Celebration meeting. Successful applications will be eligible for inclusion in the NIHR portfolio and are encouraged to gain support from a Royal College of Surgeons of England Surgical Interventional Trials Unit (SITU). ## _**Endorsement of Regional Events**_ The Association aspires to engage with oncologists and Societies on the regional level. Via its network of Regional Representatives, BASO had been supporting various regional and national meetings. However, the participation has been limited during this accounting year due to the post pandemic challenges. ## _**Engagement with Medical Students**_ In the spirit of encouraging the future generation of surgical oncologists, the Association has opened its Trainees membership to Foundation Year Trainees and Medical Students those wishing to pursue surgical oncology. BASO aims to offer support with their surgical career by providing skills courses, mentoring sessions, and guiding surgical portfolio via our wealth of regional representatives. -3- **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **TRUSTEES' ANNUAL REPORT (continued)** ## **YEAR ENDED 30 JUNE 2022** The Society is actively engaging with undergraduate Medical Societies by sponsoring their annual meeting with BASO Prize and sponsored lectures. ## _**BASO Trainees Group**_ BASO Trainees group continued growing their outlook and strengthened their links with trainees groups from across Europe. Through these collaborations, we encouraged trainees in tenets of research and clinical excellence in surgical oncology through the sponsored prizes at national specialty meetings. Our Trainees group continues to focus on research, academic training, and fellowships. ## _**BASO’s contribution to NICE consultations and Cancer CRGs**_ The Society continues to make its mark and offers expert advice on numerous site-specific Surgical Cancer consultations as requested by NICE. Our Council members sit on various Cancer CRG’s, offering expert advice. Overall, the Society is maintaining healthy relations with all the surgical societies, the Royal Colleges, and exploring collaborative working opportunities. ## **Achievements and Performance** The Society continues to support the training and educational needs of our colleagues and address the challenges faced post pandemic. BASO has demonstrated the need for an umbrella organisation to speak with one voice, and is growing its membership, maintained steady finances and delivered another successful virtual meeting this year. ## _**Zenith Global Health Award 2021**_ BASO is honoured to have been presented the 2021 Zenith Global Health Award in recognition for the Society’s contribution to the clinical education and research. ## _**COVID –19**_ BASO continued to support the CovidSurg-Cancer Study and is one of the key sponsors of this study. CovidSurg-Cancer is an international cohort study, designed by the team in Birmingham to assess the safety of surgery for all types of cancer during COVID-19 pandemic and the impact of pandemic in cancer delay and treatment pathways. BASO, as the non-commercial NIHR partner, is one of the Societies that offers a small surgical research grant to this study which would entitle it to be listed on the NIHR Portfolio. Our Trustees hope to continue providing support to our members and cancer community to get through the post-pandemic pressures and challenges. ## _**BASO Annual Meeting**_ To support the ongoing education needs of its members and surgical community, BASO delivered its second virtual Annual Meeting. The meeting was themed on “Innovation in cancer surgery” and was delivered under the leadership of our immediate Past-President Mr Hassan Malik, and Professor Jim Khan, Meeting Secretary. Conference was delivered via the BASO’s (first virtual) event app boosting the engagement and network opportunities. Meeting was facilitated by an array of international speakers and panellists, all esteemed surgeons in the field of surgical oncology and had an attendance of 283 delegates. The feedback received from delegates and speakers was extremely positive, both about the content of the programme and the virtual organisation. -4- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **TRUSTEES' ANNUAL REPORT (continued)** ## **YEAR ENDED 30 JUNE 2022** 100 abstracts were presented under oral or poster presentation sessions, and 9 prizes were awarded for best abstract presentations. The meeting also saw several prestigious eponymous lifetime achievement awards and orations given to some of the leading surgeons of our times. Meeting recruited 33 new members and generated a small profit. The program was packed with some stellar speakers and exciting sessions, hot debates, specialty updates, in conversation with and latest news on surgical education from around the world. The key highlights of the programme were: - Virtual presentations of oral and poster abstracts presentations. - Launched new prize session for Medical Students. - Live Q&A opportunities for delegates and panels. - BASO Trainees/Skills Day is focused on the themes of simulation, innovation and artificial intelligence. - Robotics feature big time in the conference program with focus on training, resources and fellowships. - This year’s meeting saw the BASO Raven Lifetime Award to Professor Robert Mansel, Geoff Oates Award to Professor Robert Steele and Uccio Querci della Rovere Award to Professor Jiong Wu. - Key note lecture by Professor Marescaux on Innovations and developments in cancer surgery and the round table discussion on the future of cancer surgery in view of emerging technologies. - Medico-legal issues in Covid times, presented an engaging presentation by Mr Robert Wheeler and Professor Peter Sagar. - Live Q&A opportunities for delegates and panels. The Association aspires to continue building on the success of this programme and making BASO meetings financially sustainable. ## _**European Journal of Surgical Oncology**_ **The EJSO** , co-owned by BASO and the ESSO continues to go from strength to strength with a rise in the quality of submission and article downloads. The 2021 impact factor were released earlier in June. The EJSO impact factor has increased to 4.533 from 4.424 from last year. (Follow link for more details: https://journalinsights.elsevier.com/journals/0748-7983/impact_factor_5_year). This is a remarkable jump in citations and credit must be given to the editorial team led by our past President Professor Riccardo Audisio (Editor in Chief). ## _**Network and links with other organisations**_ T he Association continues to grow and strengthen its links with other specialties and to re-establish itself as the umbrella organisation for cancer surgeons, including forming membership links with other specialties, providing consultations, and setting up partnerships for joint conferences in future. Our **BASO Trainees Group** is also proactively expanding its partnership opportunities and has representation on the ASiT Council. BASO Trainees maintains a portfolio of Trainees Prizes of £100 each for the best surgical oncology presentations at the Annual ASiT Conference, and SCTS Annual Meeting held this year. -5- **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **TRUSTEES' ANNUAL REPORT (continued)** ## **YEAR ENDED 30 JUNE 2022** This year, to promote collaborative work, BASOTrainees joined forces with Dukes Club and Roux Club to deliver a joint meeting on ‘Essentials of Surgical Research’ focused on surgical trainees at the early stage of research pathway. It was a successful event facilitated by expert speakers. ## **European Society of Surgical Oncology** BASO had signed a ’memorandum-of-understanding’ with our European sister society **ESSO** to strengthen the affiliation between the two societies. BASO members did get affiliate membership to ESSO, however, with the updated agreement, BASO members now enjoy standard membership benefits of ESSO including reduced registration rates to the ESSO Annual conference, courses and training programmes. BASO members also get the opportunity to apply to an international career development programme and access to the membership restricted areas to the ESSO website. BASO individuals will now have the voting right at the ESSO General Assembly. ## **NIHR’s Clinical Research Network** The Association also maintains its relationship with the NIHR’s Clinical Research Network, and supports the ‘Tomorrow’s Leaders’ programme which enrols the future leaders in the field of surgical oncology and research. These leaders are encouraged to join our trainees' membership and are offered support to enhance their career in surgical oncology via short workshops, methodology training, research grant, etc. ## **National Clinical Guidelines** BASO continues to maintain a strong presence when National Clinical Guidelines are either developed or updated. BASO Trustees are appointed as the Specialist Advisors for the NICE’s Interventional Procedure Programmes. Furthermore, BASO Trustees have been contributing to numerous consultations, and are active members of the different Cancer Commissioning Groups. ## **All-Party Parliamentary Group on Cancer** BASO Council is pleased to announce its representation as a stakeholder in the All-Party Parliamentary Group on Cancer. BASO Council is confident that this offers BASO a strong position to discuss with policymakers and lobby for the benefit of oncology surgeons. ## **Health and Social Care Committee Cancer Services Expert Panel** BASO Trustees represented at the roundtable meeting to share views on a number of pledges that government has made to improve cancer services in England. It was a productive meeting and helped voice BASO’s concerns, and raised the Society’s profile and engagement. ## **BASO@ UK Oncology Forum** BASO maintains an ongoing collaboration with the UK Oncology Forum and delivers a pan-tumour session every year. This national clinically focussed meeting is open to UK Cancer HCPs and is free for BASO members to attend. The meeting is focused on oncologists and offers BASO a strong presence. BASO Council aims to develop this collaboration further. -6- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **TRUSTEES' ANNUAL REPORT (continued) YEAR ENDED 30 JUNE 2022** ## **BASO@ Oncology Professional Care** This year, BASO collaborated with the OPC22, a two-day meeting held at London ExCel, and facilitated five sessions. The meeting is designed for Clinical Nurse Specialists, Oncology Nurse Leads, Cancer Researchers, Staff Grade Doctors, Palliative Medicine Consultants, Cancer Pharmacists, and Radiographers etc. The meeting was a success and had an attendance of 1300 delegates. The meeting is heavily sponsored by the industry and so was free for BASO members and non-members and was CPD accredited. BASO Council intends to develop a continued partnership based on the success of this meeting. ## **Cancer Services Committee** BASO~ACS continues chairing the RCSENG’s **Cancer Services Committee** , and is now invited to offer expert advice towards the ‘Future of Surgery’ Commission, and has contributed on ‘Restructuring of the MDTs’, and GMC’s proposal on Draft Credentialing Frame Work. As a surgical oncology society, we are actively engaged in decision making with organisations such as NICE, NCEPOD, Specialist Cancer CRG, the Royal College of Surgeons, and GMC. ## **BASO Publications** In addition, this accounting year, BASO also engaged with and contributed to: - In December 2021, BASO worked with Health Awareness on the 2021 Innovations in Oncology campaign and produced an article on ‘ **Protected: Liver transplantation: A new treatment for unresectable liver metastases’** . This article was prepared by Professor Derek Manas, BASO Trustee and Dr Afsana Elanko, Director of Education. - In October 2021, BASO contributed with the article **‘** _**Finding New Methods of Bowel Cancer Screening’**_ on Health Awareness on the 2021 Innovations in Oncology campaign. The article was prepared by Mr Edmund Leung, BASO Trustee and Dr Afsana Elanko, Director of Education. ## **BASO Endorsed Meetings** This year, BASO endorsed the following events and meetings: - Colorectal FRCS viva practice webinar: 2[nd] July 2021 - ESSO HPB course: 8-10 Nov 2021 - Essentials of Surgical Research: 20[th] May 2022 - Portsmouth Colorectal Congress (6[th] Edition): 15-18 June 2022 - Joint ESSO/BASO Webinar – Controversies in rectal cancer management – Consultant’s corner: 16[th] July 2022 - TUGS HPB WEBINARS: Hilar Cholangiocarcinoma & Biliary Strictures BASO~ACS continues to support and promote the development of cancer treatment, research, patient care, and education and training of our future generation of oncologists. ## **Financial Review** ## _**Membership**_ Membership of the Association remains stable during the course of the year. Membership subscriptions for 2021-22 continued to be kept intentionally low at £180 for full membership as the Association still holds high levels of reserves. -7- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **TRUSTEES' ANNUAL REPORT (continued)** ## **YEAR ENDED 30 JUNE 2022** The subscription for the BASO Trainees for 2021-22 was also unchanged. As agreed at the 2017 AGM, BASO offers a 50% discounted fee to the Full Membership of the BASO~ACS for two years to a BASO Trainees member upon completion of training, provided they were the paying member of the Society for two consecutive years. ## _**EJSO**_ The profits from the EJSO are offset against the cost of th membership subscriptions to the EJSO and these are included in the final reconciliation. A new Journal Publishing agreement between ESSO and BASO as owners, and Elsevier as publishers of the Journal, was made as of 9[th] December 2020. Elsevier paid a one-off signing bonus of £50,000 to both the Societies that was split 50:50 between BASO and ESSO. This new agreement with added benefits and revenues for both the Societies began on 1[st] January 2021 and shall conclude on 31[st] December 2027. All the parties agreed to meet between Sep-Dec 2024 to review the performance of the Journal in light of expectations and overall market conditions. The updated agreement and the EJSO progression will secure the future income stream for BASO. The Journal has generated a healthy profit for BASO~ACS in 2021 with an income of £69,489 after the deduction of BASO’s membership subscription for the year. It is hoped that the EJSO will continue to grow under the editorship of Professor Riccardo A Audisio. ## _**BASO Grants and Prizes**_ **1. BASO (NIHR) Research Project Grant** The 2021 BASO NIHR Research Project Grant of £5,750 was awarded in support of your project “ _Augmentation of Volatile Organic Compounds of Oesophageal Adenocarcinoma from the Tumour Lipidome (the AVOCADO study)_ .” **2. Ronald Raven Travelling Fellowship Grant** of **£3,000 in total** was awarded to: - **Mark Wilkie** ,(TiG) Fellow in Head & Neck Surgical Oncology, Manchester Royal Infirmary - **Nick Eastley** , ST8 Trauma & Orthopaedics, East Midlands (South) **3. BASO Trainees Prize** were awarded at the following external meetings: - SCTS Annual Scientific Meeting - ASiT Annual Conference ## _**BASO Annual Meeting 2021**_ BASO Trustees strongly feel that the Charity’s continues fulfilling its objective by promoting and sponsoring advancement in research and education of surgical oncology through another successful meeting. The meeting was supported by industry sponsorship and had relatively lower costs. Overall the meeting generated a small profit. The conference raised the Association’s presence in the field of Cancer research and has helped engage with various organisations and groups; and offered a great networking platform for the BASO members; recruiting new members. The Association maintains a strong level of reserves and has acquired a new income stream with the EJSO; we can continue to invest our reserves in the promotion of education, training and research via our Annual Conferences. However, we do hope to move towards a cost-neutral financial structure. -8- **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **TRUSTEES' ANNUAL REPORT (continued)** ## **YEAR ENDED 30 JUNE 2022** ## **Structure, Governance and Management** On 1st July 2010 a transfer was made from the unincorporated charity, BASO ~ The Association for Cancer Surgery, to the company limited by guarantee of the same name (Company number: 7225131, Limited by Guarantee and Registered as Charity No 1136067). The company was incorporated on the 15th April 2010 when new Articles were established. Simultaneous transfers were made to the new Association of Breast Surgery, which is also a company limited by guarantee (Company No 7207053 and Registered as Charity 1135699). The two Associations are thus legally independent of each other, with a service agreement between the two Associations to allow for the provision of a shared office and administration. Whilst the degree of separation has increased over time to allow both Associations to evolve and develop their individual identities, they share many goals and continue to work cooperatively together. In May 2020 both the Associations separated their joint database and IT services, and agreed to retain historic records of joint members or those members of ABS who have attended BASO events and viceversa. The service agreement is subject to periodic review to ensure its continuing relevance and fairness to both Associations. No further substantive changes are envisaged at this stage. The Ordinary Members of the BASO~ACS National Committee (who are also Trustees and Directors) are elected by a ballot of the Membership of the Association, following a ‘Call for Nominations’. Officer posts are notified to the Membership by a call for nominations, followed by a ballot of Trustees if there is more than one candidate. All Honorary Officers are also Trustees and Directors. All appointments are confirmed by the Membership at the AGM. BASO~ACS has National Committee meetings four times a year. BASO also administer the Royal College of Surgeons of England’s Cancer Services Committee, which meets three times a year and is chaired by the President of BASO~ACS. The main business of BASO~ACS is decided upon at its National Committee meetings. Decisions in-between times are made by phone or e-mail communication between the Honorary Officers, with day-to-day issues being dealt with by the Association Manager in liaison with the Honorary Officers. The Trustees/Directors regularly review the major risks that the charity faces and its reserve policy, combined with an annual internal audit of the controls over key financial systems, which are designed to provide sufficient resources in the event of adverse conditions. No major risks have been identified by the Trustees during the year. The Trustees pay due regard to the Charity Commission’s guidance on public benefit when deciding what activities the Charity should undertake. ## **Reserves Policy** BASO ~ ACS holds a sufficient reserve to allow the society to meet financial obligations in the event of a financial loss following an annual conference, to maintain the low level of conference fees for delegates and to obviate the need for increases in Membership fees. The level of reserves, and income from conferences and subscriptions, is crucial to the Association’s work and objectives, and is monitored carefully to ensure a balance between a secure financial position for the Association and minimal costs to Members and potential Members. ## **Investment Policy** The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association’s reserves. -9- **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **TRUSTEES' ANNUAL REPORT (continued)** ## **YEAR ENDED 30 JUNE 2022** ## **Plans for the Future** Growth of the core membership and the breadth of specialisms represented were set out as key aims for 2021-22. Whilst overall growth has not materialised, membership numbers have remained steady and the Trustees are actively seeking stronger links with other Associations, many of whom have been invited to nominate observers to Council meetings and to whose meetings we have offered to send observers, with the intention of improving communication and understanding in areas of common interest. Several of these Associations have expressed an interest and the Trustees look forward to reporting on progress in this area in future. The present Trustees themselves represent a broad cross-section of specialisms and so bring a welcome breadth of experience and perspective to the steering process. BASO Trustees intend to establish affiliation support for smaller complex cancer surgical groups, offering them affiliation to BASO membership and endorsement of their meeting, etc., thereby expanding the Association’s distinctive “brand” as the umbrella Society for all Cancer Surgeons. To this end, in 2010-22 the Association has made significant contribution to different consultations as organised by NICE. The Trustees are actively developing collaborations with different Royal Colleges, Cancer Commissioning Boards/Reference Groups, Public Health England, GMC and many other interested parties with the aim – as always - of sharing knowledge, opening out debate and improving best practice for the benefit of cancer patients. The Cancer Services Committee is currently reviewing the issue of ‘complex surgical oncology training’, ‘Fellowship training recommendations for cancer surgery ‘and ‘Cancer Recovery Task Force’. BASO has been invited to contribute to the ‘future of surgery’ commissioning of the RCS; and the CSC would ideally aspire to have direct representation on the RCS Council. The Cancer Services Committee has also been invited to be involved in setting the quality metrics for cancer surgery for the UK, in conjunction with CRUK and NCIN. BASO Trustees have joined the Specialised Cancer Clinical Commissioning Group and using its wealth of experts are supporting service development in cancer surgery. BASO will continue to fund research grants in partnership with Rosetrees Trust to support surgical oncology research. This initiative will foster increasing the breadth of surgical research, and the shortlisted studies will be suitable for inclusion in the NIHR portfolio studies. BASO will extend its sponsorship and support to regional level meetings, and Student Surgical Societies. BASO Trainees membership is now open to Medical Students and Foundation Year Trainees, those interested in surgical oncology, with the aim to support their training and further education & career in cancer surgery. As training and work pressures change with an ever-evolving healthcare service, our BASO Trainees group intends to improve the experience, training, and professional competence of surgical trainees with an interest in oncology, principally in academic and research matters. This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006. Approved by the Trustees on 20 November 2022 and signed on their behalf by: ......................................... **Mr Michael Shackcloth Honorary Treasurer** -10- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES** ## **YEAR ENDED 30 JUNE 2022** I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2022 which are set out on pages 12 to 19. ## **Responsibilities and basis of report** As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act. ## **Independent examiner's statement** I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or 2. the accounts do not accord with those records; or 3. the accounts do not comply with the accounting requirements of section 396 of the 2006Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or 4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. ## **C A Barker FCA** Edmund Carr LLP 146 New London Road Chelmsford CM2 0AW 23 November 2022 -11- **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT)** ## **YEAR ENDED 30 JUNE 2022** |**Note**
**£**
**£**
**INCOME from:**
Charitable activities:
Members' subscriptions
33,949
-
Scientific conference
**2**
18,670
-
Publications - EJSO
80,270
-
Other trading activities
10
-
Investments
**3**
132
49
**TOTAL INCOME**
133,031
49
**EXPENDITURE on:**
Charitable activities
Subscriptions - ESSO
7,464
-
Scientific conference
**2**
10,184
-
Publications - EJSO
10,781
-
Fellowships & awards
**4**
10,669
4,000
National Committee and support costs **5**
68,045
-
**TOTAL EXPENDITURE**
107,143
4,000
**NET INCOME/(EXPENDITURE)**
25,888
(3,951)
Transfers between funds
-
-
**NET MOVEMENT IN FUNDS**
25,888
(3,951)
**RECONCILIATION OF FUNDS**
Total funds brought forward
254,732
33,455
Total funds carried forward
280,620
29,504
**Unrestricted**
**Funds**
**Funds**
**Restricted**|**Total Funds **
**2022**
**£**
33,949
18,670
80,270
10
181
133,080
7,464
10,184
10,781
14,669
68,045
111,143
21,937
-
-
288,187
310,124|**Total Funds**
**2021**
£
32,836
4,110
101,547
47
199
138,739
7,366
3,188
11,180
4,500
53,331
79,565
59,174
-
-
229,013
288,187| |---|---|---| The charity has no recognised gains or losses other than the results for the period as set out above. **The notes on pages 14 to 19 form part of these financial statements.** -12- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **BALANCE SHEET AS AT 30 JUNE 2022** |**Note**
**FIXED ASSETS**
Tangible assets
**10**
**CURRENT ASSETS**
Debtors
**11**
Cash at bank
**CREDITORS: Amounts falling due**
**within one year**
**12**
**NET CURRENT ASSETS**
**TOTAL ASSETS LESS CURRENT LIABILITIES**
**NET ASSETS**
**FUNDS**
Unrestricted
**13**
Restricted
**14**
**TOTAL FUNDS**|**£**
**£**
566
19,122
362,103
381,225
(71,667)
309,558
310,124
310,124
280,620
29,504
310,124
**2022**|**£**
**£**
704
11,188
340,605
351,793
(64,310)
287,483
288,187
288,187
254,732
33,455
288,187
**2021**| |---|---|---| For the year ending 30 June 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Directors' responsibilities: - The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; - The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019). These financial statements were approved by the Trustees on 20 November 2022 and are signed on their behalf by: …................................................... **MR ZAED HAMADY** …................................................... **MR MICHAEL SHACKCLOTH** Company Registration Number: 7225131 **The notes on pages 14 to 19 form part of these financial statements.** -13- **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **NOTES TO THE FINANCIAL STATEMENTS** ## **YEAR ENDED 30 JUNE 2022** ## **1. ACCOUNTING POLICIES** ## **Basis of accounting** The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee. ## **Going Concern** The financial statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern. ## **Incoming Resources** Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt. ## **Resources Expended** All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity. Staff and office costs are recharged to the charity under the service agreement with ABS. ## **Debtors and creditors** Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount. ## **Cash and cash equivalents** Cash and cash equivalents comprise cash on hand and deposits. ## **Fixed Assets and Depreciation** Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows: Computer equipment 25% reducing balance Fixtures & fittings 25% reducing balance -14- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS** ## **YEAR ENDED 30 JUNE 2022** ## **ACCOUNTING POLICIES continued** ## **Fund accounting** Funds held by the charity are either: Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees. Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity. ## **2. CHARITABLE ACTIVITIES SCIENTIFIC CONFERENCE** |**Income**
Fees
Lecture grants
**Expenditure**
Speaker expenses
Venue and catering costs
Other conference costs|**Unrestricted**
**Funds**
**£**
16,670
2,000
18,670
-
-
10,184
10,184|**Restricted**
**Funds**
**£**
-
-
-
-
-
-
-|**Total Funds**
**2022**
**£**
16,670
2,000
18,670
-
-
10,184
10,184|**Total Funds**
**2021**
**£**
4,110
-
4,110
-
-
3,188
3,188| |---|---|---|---|---| All conference income and expenditure in 2021 was unrestricted. ## **3. INVESTMENT INCOME** All of the charity's investment income arises from interest bearing deposit accounts. ## **4. FELLOWSHIPS & AWARDS** |Ronald Raven Prize
Ronald Raven Travel Scholarships
Alan Edwards Memorial Fund
Other awards and medals|**Unrestricted**
**Funds**
**£**
-
-
-
10,669
10,669|**Restricted**
**Funds**
**£**
600
3,000
400
-
4,000|**Total Funds**
**2022**
**£**
600
3,000
400
10,669
14,669|**Total Funds**
**2021**
**£**
600
3,000
400
500
4,500| |---|---|---|---|---| In 2021 Other Awards were paid from unrestricted funds. All other prizes were paid from restricted funds. -15- **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **NOTES TO THE FINANCIAL STATEMENTS** ## **YEAR ENDED 30 JUNE 2022** ## **5. NATIONAL COMMITTEE & SUPPORT COSTS** |Staff salaries and pension costs
Other support costs
Governance costs (note 6)
National committee costs
Service agreement charges|**Unrestricted**
**Funds**
**£**
50,111
1,457
-
11,798
4,679
68,045|**Restricted**
**Funds**
**£**
-
-
-
-
-
-|**Total Funds**
**2022**
**£**
50,111
1,457
-
11,798
4,679
68,045|**Total Funds**
**2021**
**£**
40,272
-
1,800
5,344
5,915
53,331| |---|---|---|---|---| All national committee and support costs in 2021 were unrestricted. ## **6. GOVERNANCE COSTS** |Accounting and payroll services
Independent examination fee
Fees payable to independent examiner
Bank charges
Other professional fees
**7. STAFF COSTS AND EMOLUMENTS**
**Total staff costs were as follows:**
Wages & salaries
Pension costs (defined contribution scheme)|**Unrestricted**
**Funds**
**£**
3,253
590
3,843
391
445
4,679|**Restricted**
**Funds**
**£**
-
-
-
-
-
-|**Total Funds**
**2022**
**£**
3,253
590
3,843
391
445
4,679
**2022**
**£**
46,394
3,717
50,111|**Total Funds**
**2021**
**£**
4,025
575
4,600
416
899
5,915
**2021**
**£**
37,072
3,200
40,272| |---|---|---|---|---| ## _**Particulars of employees:**_ The average number of employees during the year was 1, (full-time equivalent - 0.8) (2021 - 1 employee and 0.8 FTE) No employee received remuneration of more than £60,000 during the period. -16- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS** ## **YEAR ENDED 30 JUNE 2022** ## **8. NET OUTGOING RESOURCES FOR THE YEAR** **----- Start of picture text -----**
|||| |---|---|---| |2022|2021| |This is stated after charging:|£|£| |Depreciation|138|168| **----- End of picture text -----**
**9. TRUSTEES' REMUNERATION** None of the Trustees were paid any remuneration by the Association during the period. Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company. Expenses totalling £760 were reimbursed to 4 trustees during the period (2021 - £188 to 1 Trustee). ## **10. TANGIBLE FIXED ASSETS** **----- Start of picture text -----**
||||| |---|---|---|---| |Computer|Fixtures| |equipment|& fittings|Total| |£|£|£| |COST| |At 1 July 2021|3,060|2,421|5,481| |Additions|-|-|-| |-|-|-| |Disposals| |At 30 June 2022|3,060|2,421|5,481| |DEPRECIATION| |At 1 July 2021|2,375|2,402|4,777| |Charge for the year|126|12|138| |At 30 June 2022|2,501|2,414|4,915| |NET BOOK VALUE| |At 30 June 2022|559|7|566| |At 30 June 2021|685|19|704| |11.|DEBTORS| |2022|2021| |£|£| |Trade debtors|300|-| |Prepayments|5,706|1,162| |Other Debtors|13,116|10,026| |19,122|11,188| **----- End of picture text -----**
-17- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE** ## **NOTES TO THE FINANCIAL STATEMENTS** ## **YEAR ENDED 30 JUNE 2022** ## **12. CREDITORS: Amounts falling due within one year** |Trade creditors
Other creditors
Accruals
Deferred income|**2022**
**£**
482
-
11,117
60,068
71,667|**2021**
**£**
-
-
8,985
55,325
64,310| |---|---|---| Deferred income relates to EJSO royalties received in advance for the following period. ## **13. UNRESTRICTED FUNDS** |**13. UNRESTRICTED FUNDS**||||| |---|---|---|---|---| |**Current year**
**Balance at**
**01/07/2021**
£
General unrestricted funds
254,732
**_Prior year_**
**_Balance at_**
**_01/07/2020_**
_£_
_General unrestricted funds_
_194,062_
**14. RESTRICTED FUNDS**
**Current year**
**Balance at**
**01/07/2021**
£
a)
Alan Edwards Memorial Fund
5,569
b)
Ronald Raven Prize Fund
2,469
c)
Ronald Raven Travelling
25,417
Fellowship Fund
33,455|**Balance at**
**01/07/2021**
£|**Incoming**
**Outgoing**
**£**
**£**
**Movement in resou**|**Transfers**
**£**
**rces:**|**Balance at**
**30/06/2022**
**£**| ||254,732|133,031
(107,143)|-|280,620| ||**_Balance at_**
**_01/07/2020_**
_£_|**_Incoming_**
**_Outgoing_**
**_£_**
**_£_**|**_Transfers_**
**_£_**|**_Balance at_**
**_30/06/2021_**
**_£_**| ||_194,062_|_138,735_
_(75,565)_|_(2,500)_|_254,732_| |||**Incoming**
**Outgoing**
**£**
**£**
9
(400)
7
(600)
33
(3,000)
49
(4,000)
**Movement in resou**|**Transfers**
**£**
-
-
-
-
**rces:**|**Balance at**
**30/06/2022**
**£**
5,178
1,876
22,450
29,504| -18- ## **BASO ~ THE ASSOCIATION FOR CANCER SURGERY COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 30 JUNE 2022** ## **14. RESTRICTED FUNDS** |**_Prior year_**
a)
_Alan Edwards Memorial Fund_
b)
_Ronald Raven Prize Fund_
c)
_Ronald Raven Travelling_
_Fellowship Fund_|**_Balance at_**
**_01/07/2020_**
_£_
_5,968_
_569_
_28,414_
_34,951_|**_Movement in resources:_**
**_Incoming_**
**_Outgoing_**
**_£_**
**_£_**
_1_
_(400)_
_-_
_(600)_
_3_
_(3,000)_
_4_
_(4,000)_|**_Transfers_**
**_£_**
_-_
_2,500_
_-_
_2,500_|**_Balance at_**
**_30/06/2021_**
**_£_**
_5,569_
_2,469_
_25,417_
_33,455_| |---|---|---|---|---| ## **15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)** |**Current year**
Restricted funds
Unrestricted funds
**_Prior year_**
_Restricted funds_
_Unrestricted funds_|**Tangible**
**fixed assets**
**£**
-
566
566
**_Tangible_**
**_fixed assets_**
**_£_**
_-_
_704_
_704_|**Other net**
**assets**
**£**
29,504
280,054
309,558
**_Other net_**
**_assets_**
**_£_**
_33,455_
_254,028_
_287,483_|**Total**
**£**
29,504
280,620
310,124
**_Total_**
**_£_**
_33,455_
_254,732_
_288,187_| |---|---|---|---| ## **16. COMPANY LIMITED BY GUARANTEE** The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound. ## **17. RELATED PARTY TRANSACTIONS** There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9. -19-